Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c00596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Paul S Riehl und 24 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States. Hauptthemen laut MEDLINE: Lysosomes, NLR Family, Pyrin Domain-Containing 3 Protein, Immunoconjugates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
An initial series of NLRP3 agonist antibody-drug conjugates (ADCs) failed to induce IL-1β in vitro due to lysosomal trapping of the payload. To address this, we developed assays and computational tools to identify a new payload that could diffuse out of the lysosomes. ADCs derived from this payload were active, emphasizing the need to avoid payload lysosomal accumulation for nonlysosomal targets. Two active ADCs necessitated attaching a cleavable valine-citrulline recognition element to the payload via a noncanonical ester linkage, rather than a canonical carbamate one, since the payload did not contain a basic amine. The citrulline stereocenter configuration was found to affect the payload release and in vitro activity. The ADC with the (L)-Val-(L)-Cit ester configuration showed superior in vitro activity, high stability in mouse serum, and rapid cleavage in human liver lysosomes. These properties suggest that this noncanonical (L)-Val-(L)-Cit ester attachment may be valuable to the ADC community moving forward.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States.
- Research and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States.
ORCID-Profile: Paul S Riehl, Meng Yao Zhang, Scott A Hollingsworth, Sayumi Yamazoe, Eugene P Chekler, Julian C Lo
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Riehl, P. S., Zhang, M. Y., Dhar, P., Wang, Z., Pan, J., Mansfield, K., Johnson, W. L., Zhang, Q., Li, Y., D'Souza, R., Zhang, J., Olsen, J., Deshpande, M., Kotapati, S., Hollingsworth, S. A., Verma, I., Li, Y. X., Su, Y., Cheng, Q., …, & Lo, J. C. (2025). Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00596
Vancouver
Riehl PS, Zhang MY, Dhar P, Wang Z, Pan J, Mansfield K, et al. Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00596
BibTeX
@article{Riehl2025,
author = {Riehl, Paul S and Zhang, Meng Yao and Dhar, Payal and Wang, Zhiying and Pan, Jie and Mansfield, Kathleen and Johnson, Walter L and Zhang, Qian and Li, Yvonne and D'Souza, Ryan and Zhang, Jun and Olsen, Jonathan and Deshpande, Madhura and Kotapati, Srikanth and Hollingsworth, Scott A and Verma, Isha and Li, Yi-Xin and Su, Yang and Cheng, Qinqin and Yamazoe, Sayumi and Micci, Luca and Broz, Miranda and Janc, James and Chekler, Eugene P and Lo, Julian C},
title = {Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c00596}
}
EUVIMED